SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Sickle Cell Disease Forecast in 10 Major Markets 2017-2027 - Research and Markets
[July 12, 2017]

Sickle Cell Disease Forecast in 10 Major Markets 2017-2027 - Research and Markets


The "Sickle Cell Disease Forecast in 10 Major Markets 2017-2027" report has been added to Research and Markets' offering.

Sickle cell disease (SCD) is a term comprising clinically relevant haemoglobinopathies caused by mutations in the HBB gene resulting in sickle haemoglobin (HbS). It is the most common genetic disorder worldwide. Clinically, SCD presents a wide variety of forms that range from mild to very severe, depending on the genotype, with a broad range of comorbidities. The most common and severe form, constituting the majority of SCD cases worldwide, is caused by a homozygous inheritance of a single point mutation in the ß globin subunit and is usually called SCD SS or sickle cell anaemia (SCA).

This report provides the current prevalent population for Sickle cell disease across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Russia, Canada ad India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Sickle cell disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Key Topics Covered:


1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis (News - Alert) & Clinical Course

7. Key Comorbid conditions/features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for sickle cell disease

10. Features of Sickle Cell Disease Patients

11. Comorbid conditions of SCD patients

12. Abbreviations used in the report

13. Patient-Based Offering

14. Online Pricing Data and Platforms

15. References

16. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/f3nx5n/sickle_cell


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy